Attached files
| file | filename |
|---|---|
| EX-5.1 - EX-5.1 - Oncotelic Therapeutics, Inc. | d573021dex51.htm |
| EX-4.12 - EX-4.12 - Oncotelic Therapeutics, Inc. | d573021dex412.htm |
| S-1 - S-1 - Oncotelic Therapeutics, Inc. | d573021ds1.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the use, in the Prospectus constituting a part of this Registration Statement on Form S-1, of our report dated April 17, 2018 (which report expresses an unqualified opinion and includes an explanatory paragraph expressing substantial doubt about the Company’s ability to continue as a going concern), relating to the financial statements of Mateon Therapeutics, Inc. included in the Annual Report on Form 10-K for the year ended December 31, 2017.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ OUM & CO. LLP
San Francisco, California
June 13, 2018